Q2 STOCKS TO BUY

Analyst Upgrades: Amazon.com, Inc., ZS Pharma Inc, and Oracle Corporation

Analysts upwardly revised their ratings and price targets on Amazon.com, Inc. (NASDAQ:AMZN), ZS Pharma Inc (NASDAQ:ZSPH), and Oracle Corporation (NYSE:ORCL)

Sep 11, 2015 at 9:10 AM
facebook X logo linkedin


Analysts are weighing in on e-tailer Amazon.com, Inc. (NASDAQ:AMZN), biotech ZS Pharma Inc (NASDAQ:ZSPH)and software giant Oracle Corporation (NYSE:ORCL). Here's a quick roundup of today's bullish brokerage notes on AMZN, ZSPH, and ORCL.

  • AMZN is pointed slightly lower ahead of the open, even after RBC raised its price target to $705 from $650 -- record-high waters. This bullish attention reflects the general opinion on the Street, where 23 of 29 brokerage firms call Amazon.com, Inc. a "buy" or better. However, even though the shares have added over 68% this year to trade at $522.24, bearish betting has been popular in the options pits. AMZN's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 1.11 is only 2 percentage points from an annual high. 

  • ZSPH added over 28% yesterday, touching an all-time high of $84.85 before closing at $74.73, on news the company is in M&A talks with fellow drugmaker Actelion Ltd. This momentum appears ready to carry over into today, with the shares positioned 5.7% higher in electronic trading. Providing an extra boost is a price-target hike to $110 at William Blair, which would mark an all-time high for ZS Pharma Inc. Considering ZSPH's recent technical performance, though, nothing is out of the question -- the shares have surged 89.6% in the past 12 months. 

  • It hasn't been a great time for ORCL shareholders, with the security lagging the S&P 500 Index (SPX) by nearly 10 percentage points during the past three months, last seen a $37.61. Additionally, the shares have struggled against their 20-day trendline over this same time frame. However, BTIG started ORCL with a "buy" rating this morning, although the bullish attention has done little to move the pre-market needle. This lackluster price action will most likely be well-received in the options pits, considering ORCL's 10-day put/call volume ratio at the ISE, CBOE, and PHLX stands at an annual high of 4.37. In other words, puts have been bought to open over calls at an annual-high clip.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here